Titre du document / Document title
Safety and tolerability of azithromycin in pediatric infectious diseases: 2003 update
Auteur(s) / Author(s)
RUUSKANEN Olli
(1) ;
Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)
(1) Department of Pediatrics, Turku University Hospitals, Turku, FINLANDE
Résumé / Abstract
Oral azithromycin suspension has been prescribed to >80 million patients. Children find the color and taste of the oral suspension of azithromycin agreeable, and the drug is well-tolerated. On average 9% of patients have treatment-related adverse events, which are most frequently gastrointestinal complaints. The side effects are mild to moderate and very seldom necessitate withdrawal of the treatment. In addition to the conventional 3-day 10-mg/kg/day regimen and the 10 mglkg on Day 1 followed by 5 mglkg on Days 2 to 5 regimens, single dose 30 mg/kg and 3-day 20-mg/kg/day regimens are well-tolerated, although these new dosages are associated with more adverse effects.
Revue / Journal Title
The Pediatric infectious disease journal
ISSN 0891-3668
CODEN PIDJEV
Source / Source
2004, vol. 23, n
o 2, SUP (43 p.) (26 ref.), pp. S135-S139
Langue / Language
Anglais
Editeur / Publisher
Lippincott, Hagerstown, MD, ETATS-UNIS
(1987)
(Revue)
Mots-clés anglais / English Keywords
Macrolide ;
Human ;
Antibiotic ;
Antibacterial agent ;
Pediatrics ;
Child ;
Review ;
Azithromycin ;
Chemotherapy ;
Treatment ;
Infection ;
Mots-clés français / French Keywords
Macrolide ;
Homme ;
Antibiotique ;
Antibactérien ;
Pédiatrie ;
Enfant ;
Article synthèse ;
Azithromycine ;
Chimiothérapie ;
Traitement ;
Infection ;
Mots-clés espagnols / Spanish Keywords
Macrólido ;
Hombre ;
Antibiótico ;
Antibacteriano ;
Pediatría ;
Niño ;
Artículo síntesis ;
Azitromicina ;
Quimioterapia ;
Tratamiento ;
Infección ;
Mots-clés d'auteur / Author Keywords
Azithromycin; pediatric; children ;
safety ;
tolerability ;
Localisation / Location
INIST-CNRS, Cote INIST : 20356, 35400011925469.0060
Nº notice refdoc (ud4) : 15533641
